NASDAQ:BCTX - Nasdaq - CA1079301091 - Common Stock - Currency: USD
NASDAQ:BCTX (2/21/2025, 8:02:58 PM)
4.42
-0.65 (-12.82%)
The current stock price of BCTX is 4.42 USD. In the past month the price decreased by -27.44%. In the past year, price decreased by -91.53%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Briacell Therapeutics Corp is a CA-based company operating in Biotechnology industry. The company is headquartered in West Vancouver, British Columbia and currently employs 17 full-time employees. The company went IPO on 2006-10-12. BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The firm is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. The company is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
BRIACELL THERAPEUTICS CORP
Suite 300 - Bellevue Centre, 235 -15th Street
West Vancouver BRITISH COLUMBIA V7T 2X1 CA
CEO: William V. Williams
Employees: 16
Company Website: https://briacell.com/
Investor Relations: http://investors.briacell.com/filings-and-shareholder-info
Phone: 16049211810
The current stock price of BCTX is 4.42 USD. The price decreased by -12.82% in the last trading session.
The exchange symbol of BRIACELL THERAPEUTICS CORP is BCTX and it is listed on the Nasdaq exchange.
BCTX stock is listed on the Nasdaq exchange.
BRIACELL THERAPEUTICS CORP (BCTX) has a market capitalization of 13.04M USD. This makes BCTX a Nano Cap stock.
BRIACELL THERAPEUTICS CORP (BCTX) currently has 16 employees.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BCTX does not pay a dividend.
BRIACELL THERAPEUTICS CORP (BCTX) will report earnings on 2025-06-12.
BRIACELL THERAPEUTICS CORP (BCTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.95).
Over the last trailing twelve months BCTX reported a non-GAAP Earnings per Share(EPS) of -4.95. The EPS decreased by -186.13% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -81.59% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 80% to BCTX. The Buy consensus is the average rating of analysts ratings from 5 analysts.